Skip to main content
PMC home page
British Journal of Clinical Pharmacology logoLink to British Journal of Clinical Pharmacology
. 1987 Dec;24(6):836–838. doi: 10.1111/j.1365-2125.1987.tb03257.x

Inhibition by erythromycin of the conversion of carbamazepine to its active 10,11-epoxide metabolite.

N Barzaghi 1, G Gatti 1, F Crema 1, M Monteleone 1, C Amione 1, L Leone 1, E Perucca 1
PMCID: PMC1386415  PMID: 3440106

Abstract

The serum levels of carbamazepine (CBZ) and its 10,11-epoxide metabolite (CBZ-E) were determined in seven subjects after a single dose of CBZ (400 mg) in the control state and during co-administration of erythromycin (500 mg three times daily for 10 days). Erythromycin treatment was associated with a decrease in CBZ clearance and a prolongation of CBZ half-life, while CBZ-E levels were markedly reduced. These data provide evidence that erythromycin inhibits the conversion of CBZ to its epoxide metabolite.

Full text

PDF
836

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Berrettini W. H. A case of erythromycin-induced carbamazepine toxicity. J Clin Psychiatry. 1986 Mar;47(3):147–147. [PubMed] [Google Scholar]
  2. Bertilsson L., Tomson T. Clinical pharmacokinetics and pharmacological effects of carbamazepine and carbamazepine-10,11-epoxide. An update. Clin Pharmacokinet. 1986 May-Jun;11(3):177–198. doi: 10.2165/00003088-198611030-00001. [DOI] [PubMed] [Google Scholar]
  3. Carranco E., Kareus J., Co S., Peak V., Al-Rajeh S. Carbamazepine toxicity induced by concurrent erythromycin therapy. Arch Neurol. 1985 Feb;42(2):187–188. doi: 10.1001/archneur.1985.04060020105023. [DOI] [PubMed] [Google Scholar]
  4. Dam M., Kristensen C. B., Hansen B. S., Christiansen J. Interaction between carbamazepine and propoxyphene in man. Acta Neurol Scand. 1977 Dec;56(6):603–607. doi: 10.1111/j.1600-0404.1977.tb01465.x. [DOI] [PubMed] [Google Scholar]
  5. Goulden K. J., Camfield P., Dooley J. M., Fraser A., Meek D. C., Renton K. W., Tibbles J. A. Severe carbamazepine intoxication after coadministration of erythromycin. J Pediatr. 1986 Jul;109(1):135–138. doi: 10.1016/s0022-3476(86)80593-5. [DOI] [PubMed] [Google Scholar]
  6. Hedrick R., Williams F., Morin R., Lamb W. A., Cate J. C., 4th Carbamazepine--erythromycin interaction leading to carbamazepine toxicity in four epileptic children. Ther Drug Monit. 1983;5(4):405–407. doi: 10.1097/00007691-198312000-00005. [DOI] [PubMed] [Google Scholar]
  7. Jaster P. J., Abbas D. Erythromycin-carbamazepine interaction. Neurology. 1986 Apr;36(4):594–595. doi: 10.1212/wnl.36.4.594b. [DOI] [PubMed] [Google Scholar]
  8. Krämer G., Theisohn M., von Unruh G. E., Eichelbaum M. Carbamazepine-danazol drug interaction: its mechanism examined by a stable isotope technique. Ther Drug Monit. 1986;8(4):387–392. [PubMed] [Google Scholar]
  9. Macphee G. J., McInnes G. T., Thompson G. G., Brodie M. J. Verapamil potentiates carbamazepine neurotoxicity: a clinically important inhibitory interaction. Lancet. 1986 Mar 29;1(8483):700–703. doi: 10.1016/s0140-6736(86)91099-8. [DOI] [PubMed] [Google Scholar]
  10. Mesdjian E., Dravet C., Cenraud B., Roger J. Carbamazepine intoxication due to triacetyloleandomycin administration in epileptic patients. Epilepsia. 1980 Oct;21(5):489–496. doi: 10.1111/j.1528-1157.1980.tb04300.x. [DOI] [PubMed] [Google Scholar]
  11. Perucca E., Gatti G., Frigo G. M., Crema A., Calzetti S., Visintini D. Disposition of sodium valproate in epileptic patients. Br J Clin Pharmacol. 1978 Jun;5(6):495–499. doi: 10.1111/j.1365-2125.1978.tb01663.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Pisani F., Fazio A., Oteri G., Perucca E., Russo M., Trio R., Pisani B., Di Perri R. Carbamazepine-viloxazine interaction in patients with epilepsy. J Neurol Neurosurg Psychiatry. 1986 Oct;49(10):1142–1145. doi: 10.1136/jnnp.49.10.1142. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Pisani F., Fazio A., Oteri G., Ruello C., Gitto C., Russo F., Perucca E. Sodium valproate and valpromide: differential interactions with carbamazepine in epileptic patients. Epilepsia. 1986 Sep-Oct;27(5):548–552. doi: 10.1111/j.1528-1157.1986.tb03582.x. [DOI] [PubMed] [Google Scholar]
  14. Sawchuk R. J., Cartier L. L. Simultaneous liquid-chromatographic determination of carbamazepine and its epoxide metabolite in plasma. Clin Chem. 1982 Oct;28(10):2127–2130. [PubMed] [Google Scholar]
  15. Vajda F. J., Bladin P. F. Carbamazepine--erythromycin-base interaction. Med J Aust. 1984 Jan 21;140(2):81–81. doi: 10.5694/j.1326-5377.1984.tb103896.x. [DOI] [PubMed] [Google Scholar]
  16. Wong Y. Y., Ludden T. M., Bell R. D. Effect of erythromycin on carbamazepine kinetics. Clin Pharmacol Ther. 1983 Apr;33(4):460–464. doi: 10.1038/clpt.1983.62. [DOI] [PubMed] [Google Scholar]
  17. Wroblewski B. A., Singer W. D., Whyte J. Carbamazepine-erythromycin interaction. Case studies and clinical significance. JAMA. 1986 Mar 7;255(9):1165–1167. doi: 10.1001/jama.255.9.1165. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Clinical Pharmacology are provided here courtesy of British Pharmacological Society

RESOURCES